Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | PRKCG | P05129 | 1/20 | 0.34 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | PRKCH | P24723 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7743524 | 0.87 | ACE2 (0.42) | ACE2OPRM1CA1SPHK1LMNA | |
| SCHEMBL21850507 | 0.85 | LMNA (0.46) | ACE2LMNA | |
| SCHEMBL7743761 | 0.83 | ACE2 (0.44) | ACE2OPRM1SPHK1LMNAGPR84 | |
| SCHEMBL7743672 | 0.83 | ACE2 (0.44) | ACE2OPRM1SPHK1LMNAGPR84 | |
| SCHEMBL15249648 | 0.81 | ACE2 (0.46) | ACE2OPRM1CA1SPHK1LMNA | |
| SCHEMBL7744252 | 0.80 | ACE2 (0.38) | ACE2OPRM1CA1SPHK1LMNA | |
| SCHEMBL7744146 | 0.80 | LMNA (0.41) | ACE2OPRM1CA1SPHK1LMNA | |
| SCHEMBL18860354 | 0.80 | ACE2 (0.38) | ACE2OPRM1CA1SPHK1LMNA | |
| SCHEMBL24357018 | 0.79 | ACE2 (0.48) | ACE2OPRM1SPHK1LMNAPRKD3 | |
| SCHEMBL7744228 | 0.79 | ACE2 (0.40) | ACE2LMNAGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256317-B2 | subjecting olefin mixture to metathesis, separating olefins, dimerizing, derivatizing (via hydroformylation) after fractionation, then alkoxylating; | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-14 | — | — | US | disclosed |
| US-20040186325-A1 | subjecting olefin mixture to metathesis, separating olefins, dimerizing, derivatizing (via hydroformylation) after fractionation, then alkoxylating; | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | disclosed |
| US-6737553-B1 | SUBJECTING A C4-OLEFIN MIXTURE TO METATHESIS, DIMERIZING, DERIVATIZING | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186325-A1 | subjecting olefin mixture to metathesis, separating olefins, dimerizing, derivatizing (via hydroformylation) after fractionation, then alkoxylating; | OSTC, ADH1C, PHOSPHO1 | ACE2 2837/4885OPRM1 670/4885CA1 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.